Company pioneering nanotechnology to bring innovative medicines that make a real difference

HRH Duke of York visiting Blueberry Therapeutics

Blueberry Therapeutics is set to create safe, effective “nanomedicines” to treat a number of unmet clinical needs.

Nanotechnology is often hailed for its potential to advance medicine, however it is not simply working at ever smaller dimensions; rather, working at the nanoscale enables scientists to utilise the unique physical, chemical, mechanical, and optical properties of materials that naturally occur at that scale. Blueberry has unique nanopolymer delivery technology that opens up huge opportunities to rapidly develop new medicines and help find ways to treat infection and inflammation.

Blueberry’s novel nanotechnology drug delivery platform allows the company to deliver drugs into cells and tissue in an efficient way, which has the potential to facilitate the development of therapies to tackle the huge healthcare needs of antibiotic resistance in bacterial infection. As they can deliver drugs so efficiently with this platform, Blueberry can

Dr Mike Davies, Co-Founder and Chief Medical Officer at Blueberry Therapeutics, commented: “Last year we secured investment that was an extremely significant stepping stone in our journey to deliver new therapies to patients suffering from serious bacterial and fungal infections. The capital will enable Blueberry to progress two anti-fungal programmes to clinical trials this year. In the short-term we are delivering a portfolio of over-the-counter products to generate revenue and thus enable the growth of Blueberry and ensure significant return to our investors.”